The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

00:27:15 2022-08-12
Sunday, the U.S. Senate passed the landmark drug pricing bill. While the pharmaceutical industry favors the bill’s Medicare out-of-pocket cap for patients, the industry has also put up a major fight against Medicare pricing negotiations, in fact deemin...
00:25:34 2022-08-05
It's earnings season—a time when publicly traded pharmas and biotechs tell their investors how they've performed over the previous quarter. But aside from drug sales figures, it’s a great opportunity to get a sense of how these companies' pipelines ha...
00:23:37 2022-07-29
Last month, Fierce hosted an event to talk with experts across the industry about what's beyond the leading edge of biotech and pharma. This week's episode brings you discussion from four of the panel discussions. Our first panel focused on Alzheimer’s ...
00:18:16 2022-07-22
If there’s been one theme that tells a story about biotech’s situation in 2023, it’s layoffs. The number of staff layoffs across the sector reached such a height that Fierce Biotech began keeping track in March with our Layoff Tracker. We'll discu...
00:29:40 2022-07-15
Biopharma watchers have been speculating for weeks about Merck & Co. buying out fellow cancer drugmaker Seagen. But now, the two companies are reportedly nearing a deal. We'll discuss how it could be the largest biopharma deal since 2020—and what m...
00:20:48 2022-07-08
FDA officials want to reform the agency's accelerated approvals program, but Paul Hastings, chair of one of biotech's leading trade organizations, has some thoughts. Reforms could limit innovation, Hastings argues, but data suggest the program could be im...
00:24:24 2022-07-01
In preparation for the fall, FDA advisors resoundingly recommended that a component of the Omicron variant be added to future vaccine doses. But just what that new vaccine formula looks like will be up to the agency to decide. We'll discuss how the commit...
00:31:22 2022-06-24
A Roche Genentech Alzheimer’s therapy failed an important clinical trial. At the press conference that followed, the scientists involved parsed over what when wrong and what should happen next. We'll discuss this conference and dive into what scientists...
00:31:49 2022-06-17
While revenue reflects how well a company’s products are selling, profit is the financial metric that really matters. It tells investors how efficiently a company is managed and how healthy the business is overall. We’ve taken a look at these ...
00:34:50 2022-06-10
Another ASCO and more CAR-T data. Arcellx presented early results on its multiple myeloma therapy at last weekend’s ASCO annual meeting, and we dig into what it would take to stand up to J&J's Carvykti. But that’s not all. P...
00:27:34 2022-06-03
Bristol Myers Squibb is once again piling on the cash for Immatics, a German immunotherapy biotech. The Big Pharma has tripled down on the collaboration, which originally kicked off in 2019 and was added to in 2021. BMS is paying $60 million upfront and $...
00:21:16 2022-05-27
When unnamed Bloomberg sources said that Dexcom is in talks to buy Insulet in what could be the year's biggest medtech megamerger, stock prices went wild. And the American Society for Clinical Oncology annual meeting, the biggest cancer conference, will b...
00:27:49 2022-05-20
Anti-TIGIT drugs were once hailed as the future of immuno-oncology. But Roche's two recent clinical trial failures for tiragolumab are raising questions about whether Big Pharmas bet on the wrong horse. Also under discussion is the sector's impressive fir...
00:35:52 2022-05-13
Biotechs have seen their valuations take a plunge, triggering layoffs and pipeline cuts, but Big Pharma is not yet tempted to go on an M&A spree. CEOs of many of the world’s biggest pharma companies point out that biotech prices still have a way...
00:30:30 2022-05-06
Biogen has been battling for a while now over Aduhelm's controversial FDA approval and subsequent narrow Medicare coverage decision. And those struggles have resulted in a significant company reorganization, including the CEO, Michel Vounatsos. After...
00:24:34 2022-05-03
Last year, as the public made Pfizer, Johnson & Johnson, and Moderna household names, pharmaceutical companies took their cue. They poured more cash into unbranded campaigns compared to past years. Also under discussion this week is an intriguing exec...